Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUDSON, AMY ROSE | 1 | 75.0% | +11.4% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 33.3% | +78.6% |
| MOLOYE, TITILAYO | 1 | 63.1% | +47.1% |
| PENNINGTON, KATIE LEIGH | 1 | 27.6% | +58.4% |
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +40.3% |
| TSAY, MARSHA M | 1 | 45.7% | +52.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034042 | VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS | HUMPHRIES, NICHOLAS ADAM | 33d |
| 17766941 | ADENO-ASSOCIATED VIRUS VECTOR PHARMACEUTICAL COMPOSITION AND METHODS | MOLOYE, TITILAYO | — |
| 17638517 | TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB | PENNINGTON, KATIE LEIGH | — |
| 17600418 | RECOMBINANT ADENO-ASSOCIATED VIRUSES AND USES THEREOF | TSAY, MARSHA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034042 | VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS | HUMPHRIES, NICHOLAS ADAM | 33d |
| 18264364 | METHODS FOR PREVENTING CARDIAC OR SKELETAL DEFECTS IN DISEASES INCLUDING MUCOPOLYSACCHARIDOSES | HUDSON, AMY ROSE | — |
| 17766941 | ADENO-ASSOCIATED VIRUS VECTOR PHARMACEUTICAL COMPOSITION AND METHODS | MOLOYE, TITILAYO | — |
| 17638517 | TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB | PENNINGTON, KATIE LEIGH | — |
| 17605486 | FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS | NOBLE, MARCIA STEPHENS | — |
| 17600418 | RECOMBINANT ADENO-ASSOCIATED VIRUSES AND USES THEREOF | TSAY, MARSHA M | — |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1636 | 1 |
| 1631 | 1 |
| 1634 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264364 | METHODS FOR PREVENTING CARDIAC OR SKELETAL DEFECTS IN DISEASES INCLUDING MUCOPOLYSACCHARIDOSES | HUDSON, AMY ROSE | 1636 | DP | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18034042 | VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS | HUMPHRIES, NICHOLAS ADAM | 1631 | §103§112 | Non-Final OA | 33d | Pending | Apr 26, 2023 |
| 17766941 | ADENO-ASSOCIATED VIRUS VECTOR PHARMACEUTICAL COMPOSITION AND METHODS | MOLOYE, TITILAYO | 1632 | §103§112 | Non-Final OA | — | Pending | Apr 06, 2022 |
| 17638517 | TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB | PENNINGTON, KATIE LEIGH | 1634 | §102§103§112 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17605486 | FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS | NOBLE, MARCIA STEPHENS | 1632 | §112DP | Final Rejection | — | Pending | Oct 21, 2021 |
| 17600418 | RECOMBINANT ADENO-ASSOCIATED VIRUSES AND USES THEREOF | TSAY, MARSHA M | 1656 | §103§112 | Non-Final OA | — | Pending | Sep 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial